Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial.
Ring H, Gilbert N, Hook R, Platt A, Smith C, Irvine F, Donaldson C, Jones E, Kelly J, Mander A, Murphy C, Pennington M, Pullen A, Redley M, Rowe S, Wason J. Ring H, et al. Among authors: platt a. Trials. 2016 Jun 24;17(1):297. doi: 10.1186/s13063-016-1429-7. Trials. 2016. PMID: 27342377 Free PMC article. Clinical Trial.
The impact of an epilepsy nurse competency framework on the costs of supporting adults with epilepsy and intellectual disability: findings from the EpAID study.
Pennington M, Ring H, Howlett J, Smith C, Redley M, Murphy C, Hook R, Platt A, Gilbert N, Jones E, Kelly J, Pullen A, Mander A, Donaldson C, Rowe S, Wason J, Irvine F. Pennington M, et al. Among authors: platt a. J Intellect Disabil Res. 2019 Dec;63(12):1391-1400. doi: 10.1111/jir.12679. Epub 2019 Aug 8. J Intellect Disabil Res. 2019. PMID: 31397022 Free PMC article. Clinical Trial.
Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT.
Ring H, Howlett J, Pennington M, Smith C, Redley M, Murphy C, Hook R, Platt A, Gilbert N, Jones E, Kelly J, Pullen A, Mander A, Donaldson C, Rowe S, Wason J, Irvine F. Ring H, et al. Among authors: platt a. Health Technol Assess. 2018 Feb;22(10):1-104. doi: 10.3310/hta22100. Health Technol Assess. 2018. PMID: 29457585 Free PMC article. Clinical Trial.
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H; COV-CHIM01 study team. Jackson S, et al. Lancet Microbe. 2024 Apr 26:S2666-5247(24)00025-9. doi: 10.1016/S2666-5247(24)00025-9. Online ahead of print. Lancet Microbe. 2024. PMID: 38703782 Free article.
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Simpson EL, et al. Among authors: platt am. Dermatol Ther (Heidelb). 2024 May 2. doi: 10.1007/s13555-024-01157-5. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38696027
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Baker T, Sharifian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, White WI, Ferrari N, Muthas D, Tummala R, Morand EF, Furie RA, Vital EM, Chamberlain C, Platt A, Al-Mossawi H, Brohawn PZ, Csomor E. Baker T, et al. Among authors: platt a. Ann Rheum Dis. 2024 May 18:ard-2023-225445. doi: 10.1136/ard-2023-225445. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38569851 Free article.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D. Silverberg JI, et al. Among authors: platt am. Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25. Am J Clin Dermatol. 2024. PMID: 38528257 Free PMC article. Clinical Trial.
366 results